Jose Fernando Moura, PhD· @FernandoOnco · X·· 2 days agoScore70
Body
NATALEE: We’re talking about saving lives!
For the first time, the 6-year update shows an overall survival benefit with adjuvant ribociclib in HR+/HER2− early breast cancer.
Is this the practice-changing evidence we’ve been waiting for?
#ESMO26 @myESMO
166 views · 2 likes · 2 reposts · 0 replies
Conference abstracts
LBA25matched by Proffered paper 1: Breast cancer, early and advanced stage
Adjuvant ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in patients (pts) with HR+/HER2− early breast cancer (EBC): NATALEE 6-y overall survival (OS) and efficacy outcomes
https://esmocongress.esmo.orgSource: Jose Fernando Moura, PhD · x.com